Curetis GmbH develops and commercializes molecular diagnostic products that are designed to address the global challenge of detecting severe infectious diseases and identifying antibiotic resistances in hospitalized patients. The company’s FDA-cleared Unyvero LRT Panel for tracheal aspirate samples and Unyvero LRT BAL for bronchoalveolar lavage samples allows hospitals to diagnose serious pneumonia infections and target effective antibiotic treatment with the help of syndromic testing.